CBD Retinal-Inflammation Research Implicated Adenosine Uptake and A2A Signaling

forensic toxicology working group members October 31, 2026 Forensic Toxicology

An ocular review describes CBD-related reductions in inflammatory signaling in retinal experiments involving endotoxin. The proposed mechanism involved preserving extracellular adenosine rather than simply activating a conventional cannabinoid receptor.

The evidence included cells and rats

The review summarizes work in primary retinal microglia and retinas from lipopolysaccharide-treated rats. Lipopolysaccharide is used experimentally to provoke an inflammatory response. CBD decreased TNF-alpha expression and inhibited adenosine uptake through equilibrative nucleoside transporter 1, or ENT1. These observations concern specified experimental systems, not a randomized trial of retinal disease in patients.

Transport and receptor signaling played different roles

Adenosine can suppress inflammatory responses but is rapidly removed from the extracellular space by uptake. Inhibiting that uptake can prolong its availability. The review attributes much of the retinal anti-inflammatory effect to A2A receptor signaling downstream of this change. ENT1 and A2A therefore describe different steps in the proposed pathway, rather than interchangeable names for a CBD receptor.

A cytokine result does not establish preserved sight

Reduced inflammatory-marker expression is informative without proving improved visual acuity, durable retinal protection or clinical efficacy. The induced endotoxin model also differs from the diverse causes of human retinal inflammation. A careful assessment names the tissue, inflammatory stimulus, marker and pathway. This preserves the mechanistic finding while leaving the clinical outcome and an appropriate treatment formulation open.

Related analysis: the broader review findings and limitations.